EDAP continues to rate higher in 2023. Positive phase 2 data investigating HIFU in rectal endometriosis adds another inflection point for investors to work by. We revised our price targets to ~$18.
EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results